Pregled bibliografske jedinice broj: 1275885
DHEA, DHEAS, BDNF and their synergistic action as a potential therapy for Alzheimer´s disease
DHEA, DHEAS, BDNF and their synergistic action as a potential therapy for Alzheimer´s disease // 8th European Virtual Congress of Pharmacology (EPHAR 2021): From Great Science to Better Medicine for Europe : Book of abstracts
Prag, Češka Republika, 2021. str. 490-490 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 1275885 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
DHEA, DHEAS, BDNF and their synergistic action as a
potential therapy for Alzheimer´s disease
Autori
Vuić, Barbara ; Nikolac Perković, Matea ; Nedić Erjavec, Gordana ; Tudor, Lucija ; Konjevod, Marcela ; Pivac, Nela ; Švob Štrac, Dubravka
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
8th European Virtual Congress of Pharmacology (EPHAR 2021): From Great Science to Better Medicine for Europe : Book of abstracts
/ - , 2021, 490-490
Skup
8th european congress of pharmacology (EPHAR 2021)
Mjesto i datum
Prag, Češka Republika, 06.12.2021. - 08.12.2021
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
Alzheimer´s disease ; DHEA ; DHEAS ; BDNF ; primary mouse neurons ; synergistic action
Sažetak
Alzheimer´s disease (AD), the most common type of dementia, is still without effective treatment. This neurodegenerative disease is characterized by progressive cognitive decline, neuronal death, as well as accumulation of amyloid beta (Aβ) senile plaques and tau neurofibrillary tangles in the brain. Neurosteroids dehydroepiandrosterone (DHEA) and its sulfate (DHEAS), potent modulators of neurogenesis, neuronal growth, differentiation and neuroprotection, decrease with age and play an important role in brain aging and neurodegeneration. One of the possible DHEA(S) mechanisms is the modulation of brain-derived neurotrophic factor (BDNF) concentrations and tyrosine kinase receptors (Trk) for BDNF. Neurotrophin BDNF is also involved in synaptic plasticity and neuronal survival and reduced expression of BDNF in AD suggests its involvement in AD pathogenesis. However, the role of BDNF and DHEA(S), as well as their interaction in AD is not clear. Therefore, we have investigated the effects of DHEA(S) and BDNF in an in vitro model of AD with a particular focus on their interactions and their joint neuroprotective potential. Primary mouse neurons were treated with Aβ oligomers, as well as with DHEA(S) and BDNF or their combination. The obtained results suggest that DHEA(S) and BDNF may promise new options for the prevention and treatment of AD.
Izvorni jezik
Engleski
Znanstvena područja
Farmacija
POVEZANOST RADA
Projekti:
HRZZ-IP-2019-04-6100 - Terapijski potencijal neurosteroida i neurotrofina u demenciji (TePoNeDe) (Švob Štrac, Dubravka, HRZZ - 2019-04) ( CroRIS)
Ustanove:
Institut "Ruđer Bošković", Zagreb
Profili:
Marcela Konjevod
(autor)
Gordana Nedić Erjavec
(autor)
Dubravka Švob Štrac
(autor)
Barbara Vuić
(autor)
Nela Pivac
(autor)
Lucija Tudor
(autor)
Matea Nikolac Perković
(autor)